Cargando...
Neratinib augments the lethality of [regorafenib + sildenafil]
Regorafenib is approved for the treatment of colorectal cancer and hepatocellular carcinoma. In the trial NCT02466802 we have discovered that regorafenib can be safely combined with the PDE5 inhibitor sildenafil in advanced solid tumor patients. The present studies determined whether the approved ER...
Gardado en:
| Publicado en: | J Cell Physiol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6322207/ https://ncbi.nlm.nih.gov/pubmed/30203445 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcp.27276 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|